Brand-New Prescription Drug Pricing
Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases
The growing cost of brand-name prescription drugs (BNPD) -- FDA-approved drug products that typically have patent protection -- is a concern for patients, payers, and providers of health care -- particularly when price increases are large and occur suddenly. A 2008 congressional hearing drew attention to some small market prescription drugs that had an extraordinary price increase -- 100% or more at a single point in time. This report examined extraordinary price increases for BNPD. It examined the: (1) frequency of extraordinary price increases for BNPD from 2000 to 2008; (2) characteristics of the BNPD that had extraordinary price increases; and (3) factors that contributed to the extraordinary price increases experienced by these BNPD. Illustrations.
- ISBN 13 : 1437927017
- ISBN 10 : 9781437927016
- Judul : Brand-New Prescription Drug Pricing
- Sub Judul : Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases
- Pengarang : John E. Dicken,
- Penerbit : DIANE Publishing
- Bahasa : en
- Tahun : 2010
- Halaman : 40
- Halaman : 40
- Google Book : https://play.google.com/store/books/details?id=S1BaOx6Ghk4C&source=gbs_api
-
Ketersediaan :
The growing cost of brand-name prescription drugs (BNPD) -- FDA-approved drug products that typically have patent protection -- is a concern for patients, payers, and providers of health care -- particularly when price increases are large ...